TEL
74
9
SRE
50
3
RCL
58
3
GPC
48
-5
ALL
38
-2
QRVO
61
-4
CME
55
3
CHRW
36
2
WAT
47
-2
BEN
40
2
PNR
65
-3
EW
40
-4
NSC
50
-3
APD
27
2
FLR
53
-2
HCA
39
2
ADSK
45
-5
SLB
45
-3
XYL
43
-6
PSA
30
2
TEL
74
9
SRE
50
3
RCL
58
3
GPC
48
-5
ALL
38
-2
QRVO
61
-4
CME
55
3
CHRW
36
2
WAT
47
-2
BEN
40
2
PNR
65
-3
EW
40
-4
NSC
50
-3
APD
27
2
FLR
53
-2
HCA
39
2
ADSK
45
-5
SLB
45
-3
XYL
43
-6
PSA
30
2
Financhill
Back

ProQR Therapeutics NV 10K Form

Sell
29

PRQR
ProQR Therapeutics NV

Last Price:
1.88
Seasonality Move:
3.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PRQR News And Ratings

See the #1 stock for the next 7 days that we like better than PRQR

PRQR Financial Statistics

Sales & Book Value

Annual Sales: $7.05M
Cash Flow: $-6.57M
Price / Cash Flow: 6.97
Annual Sales: $0.56
Price / Book: 3.34

Profitability

EPS (TTM): -0.37880
Net Income (TTM): $-30.43M
Gross Margin: $0
Return on Equity: -53.15%
Return on Assets: -18.57%

ProQR Therapeutics NV Earnings Forecast

Key ProQR Therapeutics NV Financial Ratios

  • The Selling, General & Administrative Expenses for PRQR have been equal to 249.25% of Gross Profit Margin.
  • The Research & Development expenses have been 386.06% of Revenue.
  • The Interest Expense is -4.28% of Operating Income.
  • The Net Earning history of PRQR is -431.67% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

ProQR Therapeutics NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PRQR
CUSIP: N71542
Website: proqr.com

Debt

Debt-to-Equity Ratio: 0.1
Current Ratio: 3.54
Quick Ratio: 3.51

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PRQR Technical Analysis vs Fundamental Analysis

Sell
29
ProQR Therapeutics NV (PRQR) is a Sell

Is ProQR Therapeutics NV a Buy or a Sell?